Benaroya Research Institute (BRI) is on a mission to predict, prevent, reverse and cure immune system diseases. We study the cells and processes within the immune system, how and why immune system diseases start, and how to rebalance the immune system back to health. Our focus spans a wide variety of immune system diseases – including autoimmune diseases, asthma, allergy and cancer – with the goal of transforming our understanding of how to prevent and treat these conditions.
Collaboration defines our work. We build teams within our institute and with partners around the world to take on some of the most difficult questions in immunology. This approach moves us closer to our vision of a healthy immune system for everyone.
Our Centers of Discovery: A pipeline from lab research to life-changing care
BRI’s research is organized around four Centers of Discovery, allowing us to accelerate advances at every stage of our work. Our centers enable us to make discoveries in the lab and provide a foundation for new and innovative therapies. They also help us to take questions directly from the clinic — such as what makes a therapy work for one person and not another — back to our labs to find meaningful answers.
Our Biorepositories
BRI is home to 11 biorepositories with thousands of blood and tissue samples that have been donated to science, spanning 20 different immune system diseases as well as healthy controls. Access to human samples allows us to closely study diseases in the lab, make new insights, and bring those insights to patient care faster.
Our Core Labs: Building and using the latest tools and technologies
Our Core Labs enable our scientists to build and use some of the most innovative tools in immunology that allow for advanced imaging, data sequencing and exploring the human genome. Each core is led by an expert in their field. Scientists across BRI and from other institutes can partner with these experts to leverage these tools and fuel discoveries in all areas of research.
Our Team: Together we discover
Collaboration is one of BRI’s core values, and our team is our biggest asset. We have built our organization to facilitate teamwork across disease areas, with experts working across fields and with partners around the globe. Shared resources like our Core Labs, Clinical Research Center and biorepositories fuel discoveries across our institute.
Featured Publications
Nov 2025
T Cell Autocrine Hyaluronan Forms Complex Structures in CD4 T Cell Cytoplasm and Plays a Critical Role in Formation of the Immune Synapse
J Histochem Cytochem
Robert B Vernon, Michel D Gooden, John A Gebe, Inkyung Kang, Caroline Stefani, Gail Workman, Adam Lacy-Hulbert, Paul L Bollyky, Thomas N Wight
Nov 2025
Rapid and label-free isolation of human peripheral blood monocytes using a reversible CD36-binding aptamer for cell capture
Biomater Sci
Melissa Ling, Nataly Kacherovsky, Abe Y Wu, Minjian Ni, Jessica A Hamerman, Suzie H Pun
Nov 2025
Multi-omic profiling reveals age-related immune dynamics in healthy adults
Nature
Qiuyu Gong, Mehul Sharma, Marla C Glass, Emma L Kuan, Aishwarya Chander, Mansi Singh, Lucas T Graybuck, Zachary J Thomson, Christian M LaFrance, Samir Rachid Zaim, Tao Peng, Lauren Y Okada, Palak C Genge, Katherine E Henderson, Elisabeth M Dornisch, Erik D Layton, Peter J Wittig, Alexander T Heubeck, Nelson M Mukuka, Julian Reading, Garrett Strawn, Teminijesu Titus-Adewunmi, Kathleen Abadie, Charles R Roll, Veronica Hernandez, Vaishnavi Parthasarathy, Tyanna J Stuckey, Blessing Musgrove, Elliott Swanson, Cara Lord, Morgan D A Weiss, Cole G Phalen, Regina R Mettey, Kevin J Lee, John B Johanneson, Erin K Kawelo, Jessica Garber, Upaasana Krishnan, Megan Smithmyer, E John Wherry, Laura A Vella, Sarah E Henrickson, Mackenzie S Kopp, Adam K Savage, Lynne A Becker, Paul Meijer, Ernest M Coffey, Jorg J Goronzy, Mikael Sigvardsson, Cate Speake, Thomas F Bumol, Ananda W Goldrath, Troy R Torgerson, Xiao-Jun Li, Peter J Skene, Jane H Buckner , Claire E Gustafson
Oct 2025
Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetes
J Clin Invest
Gabriele Sassi, Pierre Lemaitre, Laia Fernández Calvo, Francesca Lodi, Álvaro Cortés Calabuig, Samal Bissenova, Amber Wouters, Laure Degroote, Marijke Viaene, Niels Vandamme, Lauren Higdon, Peter S Linsley, S Alice Long, Chantal Mathieu, Conny Gysemans
Oct 2025
T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes
J Immunother Cancer
Ariadna Bartoló-Ibars, Andrea Aran, Alexandra M Johansson, Valentín Ortiz-Maldonado, Nela Klein-González, Anna Alonso-Saladrigues, Eddie James, Alvaro Urbano-Ispizua, Susana Rives, Julio Delgado, Europa Azucena González-Navarro, William W Kwok, Manel Juan
